Impact of Medicaid Expansion on Access to Opioid Analgesic Medications and Medication-Assisted Treatment
Bibliographic Data
Objectives. To assess the impact of the expansion of Medicaid eligibility in the United States on the opioid epidemic, as measured through increased access to opioid analgesic medications and medication-assisted treatment. Methods. Using Medicaid enrollment and reimbursement data from 2011 to 2016 in all states, we evaluated prescribing patterns of opioids and the 3 Food and Drug Administration–approved medications used in treating opioid use disorders by using 2 statistical models. We used difference-in-differences and interrupted time series models to measure prescribing rates before and after state expansions. Results. Although opioid prescribing per Medicaid enrollee increased overall, we observed no statistical difference between expansion and nonexpansion states. By contrast, per-enrollee rates of buprenorphine and naltrexone prescribing increased more than 200% after states expanded eligibility, while increasing by less than 50% in states that did not expand. Methadone prescribing decreased in all states in this period, with larger decreases in expansion states. Conclusions. The Medicaid expansion enrolled a population no more likely to be prescribed opioids than the base Medicaid population while significantly increasing uptake of 2 drugs used in medication-assisted treatment
Analgesic · Family medicine · Health care · Medicaid · Medication adherence · Opioid · Opioid epidemic · Opioid use disorder · Psychiatry · Healthcare Policy and Management · Internal Medicine · Medicine · Opioid Use Disorder Treatment · Substance Abuse Treatment and Outcomes
Responding to the opioid crisis in North America and beyond
Trends in Methadone Use for Pain and Opioid Use Disorder Among Medicaid Enrollees
Recovery homes, regulation, & medication for opioid use disorder
State Medicaid Policies Governing Access to Medications for Opioid Use Disorder (Moud) and Moud Treatment Use in a Large Sample of People Who Inject Drugs in 20 U.S. States
Reproductive-Age Women's Experience of Accessing Treatment for Opioid Use Disorder
Bridging the gaps
Continuing increased access to buprenorphine in the United States via telemedicine after Covid-19
How do restrictions on opioid prescribing, harm reduction, and treatment coverage policies relate to opioid overdose deaths in the United States in 2013–2020? An application of a new state opioid policy scale
Simulated impact of medicaid expansion on the economic burden of opioid use disorder in North Carolina
Factors associated with state legislators’ support for opioid use disorder parity laws
The impact of state-level prenatal substance use policies on infant foster care entry in the United States
Medications for Opioid Use Disorder and Retention in Non-Intensive Outpatient Treatment
Effects of the Affordable Care Act Medicaid Expansion on Subjective Well-Being in the US Adult Population, 2010–2016
Medicaid Expansion and Prescription Trends
Measurement Approaches to Estimating Methadone Continuity in Opioid Use Disorder Care
The Role of State Medicaid Expansions in Integrating Comprehensive Mental Health Services into Opioid Treatment Programs
American Federalism and Health Policy Spillovers
More Than an Opioid Crisis
| Unique citing works | 18 |
|---|---|
| Citations per year | 2,57 |
| Citation span | 2019 - 2025 (7) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 18 |